\u200bEvaluation of Terminalia arjuna in Comparison to Taurine against Experimental Nephrotoxicity due to Cisplatin in Rats

Abstract

Background: Cisplatin is one of the most remarkable solutions in ‘the war on cancer’. Although cisplatin has been a mainstay for cancer therapy, its use is mainly limited by nephrotoxicity. The current study was aimed to evaluate the ameliorative potential of Terminalia arjuna (TA) in comparison to taurine against cisplatin toxicity.\nMethods: A total of 36 male Wistar rats were divided into 6 groups of 6 rats in each. Group 1 was normal control. Cisplatin @ 5 mg/kg b.wt was injected on day 1 to groups 2, 5 and 6. Aqueous leaf extract of Terminalia arjuna was administered orally @ 400 mg/kg b. wt to groups 3, 5 and Groups 4, 6 recieved taurine orally @ 1000 mg/kg b.wt for 14 days. Blood samples were collected from animals to assess Kidney function tests, oxidative stress and cytokines and renal tissues were examined for histological changes, if any. Result: Antioxidant profile, serobiochemical and cytokine parameters were significantly (P less than 0.05) increased and histopathological studies revealed degenerative changes and marked infiltration in the kidney of group 2 when compared to groups 1, 3 and 4. However, These changes were reversed in groups 5 and 6 that were administered with Terminalia arjuna and taurine, respectively. In conclusion, the results of the present investigation elucidated that both Terminalia arjuna and taurine have potent nephroprotective activity in cisplatin injected Wistar rats.\n